Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients : DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab

NCT Number	NCT02889523
Lead Sponsor	The Lymphoma Academic Research Organisation Collaborators: Epizyme, Inc.
Conditions	Lymphoma, DLBCL, Follicular Lymphoma
Enrollment	214 participants
Start Date	2016-10
Primary Completion	2023-01-31 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-11